Changes in clinical presentation, management and outcome in 1348 patients with differentiated thyroid carcinoma: Experience in a single institute in Hong Kong, 1960-2000

Clinical Oncology

Volumn 15, Issue 6, 2003, Pages 329-336

  Chow, Sin Ming ^a   Law, S C K ^a   Au, S K ^a   Mang, O ^b   Yau, S ^a   Yuen, K T ^a   Lau, W H ^b  

^a QUEEN ELIZABETH HOSPITAL   (Hong Kong)

^b Hong Kong Cancer Registry ^*  (China)

Author keywords

Differentiated thyroid carcinoma; Follicular carcinoma; Outcome; Papillary carcinoma; Presentation

Indexed keywords

IODINE 131; RADIOACTIVE IODINE; THYROXINE;

ADULT; ARTICLE; CANCER CENTER; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; EARLY DIAGNOSIS; FEMALE; FOLLICULAR CARCINOMA; HONG KONG; HUMAN; INCIDENCE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; PAPILLARY CARCINOMA; PRIORITY JOURNAL; REGRESSION ANALYSIS; SUBTOTAL THYROIDECTOMY; THYROID CARCINOMA; TREATMENT OUTCOME; TUMOR VOLUME;

EID: 0041910987     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0936-6555(03)00066-9     Document Type: Article

References (56)

1. Franceschi S, La Vecchia Z. Thyroid cancer (review). Cancer Surveys. Trends in Cancer Incidence and Mortality 1994; 19/20:393-422.
2. Cancer incidence and mortality in Hong Kong 1998-1999. Hong Kong Cancer Registry, Hong Kong, 2000.
3. Chow SM, Law SC, Mendenhall WM, et al. Papillary thyroid carcinoma: prognostic factors and the role of radioiodine and external radiotherapy. Int J Radiat Oncol Biol Phys 2002;52:784-795.
4. Chow SM, Law SC, Mendenhall M, et al. Follicular thyroid carcinoma: prognostic factors and the role of radioiodine. Cancer 2002;95:488-498.
5. Chow SM, Law SC, Au SK, et al. Differentiated thyroid carcinoma: comparison between papillary and follicular carcinoma in a single institute. Head Neck 2002;24:670-677.
6. Fahey TJ 3rd, Reeve TS, Delbridge L. Increasing incidence and changing presentation of thyroid cancer over a 30-year period. Br J Surg 1995;82:518-520.
7. Yamashita H, Noguchi S, Murakami N, et al. Changing trends and prognoses for patients with papillary thyroid cancer. Arch Surg 1998;133:1058-1065.
8. Freitag T, Baier A, Dewitz D. Age and sex distribution of primary thyroid cancer in relation to histological type. Zentralbl Chir 1999;124:331-335.
9. Deandrea M, Gallone G, Veglio M, et al. Thyroid cancer histotype changes as observed in a major general hospital in a 21-year period. J Endocrinol Invest 1997;20:52-58.
10. Ezaki H, Ebihara S, Fujimoto Y, et al. Analysis of thyroid carcinoma based on material registered in Japan during 1977-1986 with special reference to predominance of papillary type. Cancer 1992;70:808-814.
11. Biersack HJ, Grunwald F. Thyroid Cancer, 1st edn. Berlin: Springer Verlig, 2001.
12. Hedinger C, Williams ED., Sobin LH. Histological typing of thyroid tumors, 2nd edn. Berlin/Heidelberg/New York Springer, 1988.
13. Klein M, Vignaud JM, Hennequin V, et al. Increased expression of the vascular endothelial growth factor is a pejorative prognosis marker in papillary thyroid carcinoma. J Clin Endocrinol Metab 2001;86:656-658.
14. Biondi B, Fazio S, Cuocolo A, et al. Impaired cardiac reserve and exercise capacity in patients receiving long-term thyrotropin suppressive therapy with levothyroxine. J Clin Endocrinol Metab 1996;81:4224-4228.
15. Peters A, Ehlers M, Blank B, et al. Excess triiodothyronine as a risk factor of coronary events. Arch Intern Med 2000;160:1993-1999.
16. Cooper DS, Specker B, Ho M, et al. Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: results from the National Thyroid Cancer Treatment Cooperative Registry. Thyroid 1998;8:737-744.
17. Chaimoff M, Raiter A, Avidan S, et al. Effect of exogenous thyroid-stimulating hormone on thyroid papillary carcinoma cells in tissue culture. Head Neck 2001;23:479-483.
18. Fleming I, Cooper JS, Henson DE, et al. AJCC Cancer Staging Manual, 5th edn., 1997.
19. Sobin LH, Wittlekind C. TNM classification of malignant tumours, 5th edn. Wiley-Liss, 1997.
20. Lin JD, Chao TC, Weng HF, et al. Clinical presentations and treatment for 74 occult thyroid carcinoma. Comparison with nonoccult thyroid carcinoma in Taiwan. Am J Clin Oncol 1996; 19:504-508.
21. Fink A, Tomlinson G, Freeman JL, et al. Occult micropapillary carcinoma associated with benign follicular thyroid disease and unrelated thyroid neoplasms. Mod Pathol 1996;9:816-820.
22. Furlan JC, Bedard Y, Rosen IB. Biologic basis for the treatment of microscopic, occult well-differentiated thyroid cancer. Surgery 2001:130:1050-1054.
23. American Association of Clinical Endocrinologists. AACE/AAES medical/surgical guidelines for clinical practice: management of thyroid carcinoma. American College of Endocrinology. Endocr Pract 2001;7:202-220.
24. NCCN Practice Guidelines in Oncology-v.1.2001. In. Version 1.2002 ed: National Comprehensive Cancer Network via internet http://www.nccn.org; 2001
25. Anonymous Guidelines for the management of thyroid cancer in adults. British Thyroid Association and Royal College of Physicians of London, 2002
26. Northern Cancer Network guidelines for management of thyroid cancer. Clin Oncol 2000;12:373-391.
27. Holzer S, Reiners C, Mann K, et al. Patterns of care for patients with primary differentiated carcinoma of the thyroid gland treated in Germany during 1996. U.S. and German Thyroid Cancer Group. Cancer 2000;89:192-201.
28. Pettersson B, Coleman MP, Ron E, et al. Iodine supplementation in Sweden and regional trends in thyroid cancer incidence by histopathologic type. Int J Cancer 1996;65:13-19.
29. Levi F, Franceschi S, Te VC, et al. Descriptive epidemiology of thyroid cancer in the Swiss Canton of Vaud. J Cancer Res Clin Oncol 1990;116:639-647.
30. Lind P, Langsteger W, Molnar M, et al. Epidemiology of thyroid diseases in iodine sufficiency. Thyroid 1998;8:1179-1183.
31. Taylor T, Specker B, Robbins J, et al. Outcome after treatment of high-risk papillary and non-Hurthle-cell follicular thyroid carcinoma. Ann Intern Med 1998;129:622-627.
32. Hay ID, Grant CS, Bergstralh EJ, et al. Unilateral total lobectomy: is it sufficient surgical treatment for patients with AMES low-risk papillary thyroid carcinoma? Surgery 1998;124:958-964; discussion 964-966.
33. Hay ID, Grant CS, Taylor WF, et al. Ipsilateral lobectomy versus bilateral lobar resection in papillary thyroid carcinoma: a retrospective analysis of surgical outcome using a novel prognostic scoring system. Surgery 1987;102:1088-1095.
34. Shah JP, Loree TR, Dharker D, et al. Lobectomy versus total thyroidectomy for differentiated carcinoma of the thyroid: a matched-pair analysis. Am J Surg 1993;166:331-335.
35. Hay ID, Thompson GB, Grant CS, et al. Papillary thyroid carcinoma managed at the mayo clinic during six decades (1940-1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World J Surg 2002;26:879-885.
36. Staunton MD. Thyroid cancer: a multivariate analysis on influence of treatment on long-term survival. Eur J Surg Oncol 1994;20:613-621.
37. DeGroot LJ, Kaplan EL, McCormick M, et al. Natural history, treatment, and course of papillary thyroid carcinoma. J Clin Endocrinol Metab 1990;71:414-424.
38. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994;97:418-428.
39. Loh KC, Greenspan FS, Gee L, et al. Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients. J Clin Endocrinol Metab 1997;82:3553-3562.
40. Tsang RW, Brierley JD, Simpson WJ, et al. The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma. Cancer 1998; 82:375-388.
41. Samaan NA, Schultz PN, Hickey RC, et al. The results of various modalities of treatment of well differentiated thyroid carcinomas: a retrospective review of 1599 patients. J Clin Endocrinol Metab 1992;75:714-720.
42. Samaan NA, Schultz PN, Haynie TP, et al. Pulmonary metastasis of differentiated thyroid carcinoma: treatment results in 101 patients. J Clin Endocrinol Metab 1985;60:376-380.
43. Schlumberger M, Challeton C, De Vathaire F, et al. Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma. J Nucl Med 1996;37:598-605.
44. Massin JP, Savoie JC, Garnier H, et al. Pulmonary metastases in differentiated thyroid carcinoma. Study of 58 cases with implications for the primary tumor treatment. Cancer 1984;53:982-992.
45. Casara D, Rubello D, Saladini G, et al. Different features of pulmonary metastases in differentiated thyroid cancer: natural history and multivariate statistical analysis of prognostic variables. J Nucl Med 1993:34:1626-1631.
46. Esik O, Nemeth G, Eller J. Prophylactic external irradiation in differentiated thyroid cancer: a retrospective study over a 30-year observation period. Oncology 1994;51:372-379.
47. Wu XL, Hu YH, Li QH, et al. Value of postoperative radiotherapy for thyroid cancer. Head Neck Surg 1987;10:107-112.
48. O'Connell ME, A'Hern RP, Harmer CL. Results of external beam radiotherapy in differentiated thyroid carcinoma: a retrospective study from the Royal Marsden Hospital. Eur J Cancer 1994;6:733-739.
49. Tubiana M, Haddad E, Schlumberger M, et al. External radiotherapy in thyroid cancers. Cancer 1985;55:2062-2071.
50. Simpson WJ, Panzarella T, Carruthers JS, et al. Papillary and follicular thyroid cancer: impact of treatment in 1578 patients. Int J Radiat Oncol Biol Phys 1988;14:1063-1075.
51. Farahati J, Reiners C, Stuschke M, et al. Differentiated thyroid cancer. Impact of adjuvant external radiotherapy in patients with perithyroidal tumor infiltration (stage pT4). Cancer 1996;77:172-180.
52. Bacher-Stier C, Riccabona G, Totsch M, et al. Incidence and clinical characteristics of thyroid carcinoma after iodine prophylaxis in an endemic goiter country. Thyroid 1997;7:733-741.
53. Rosenthal DS. Changing trends. CA Cancer J Clin 1998;48:3-4.
54. Franceschi M, Kusic Z, Franceschi D, et al. Thyroglobulin determination, neck ultrasonography and iodine-131 whole-body scintigraphy in differentiated thyroid carcinoma. J Nucl Med 1996; 37:446-451.
55. Rodriguez JM, Reus M, Moreno A, et al. High-resolution ultrasound associated with aspiration biopsy in the follow-up of patients with differentiated thyroid cancer. Otolaryngol Head Neck Surg 1997;117:694-697.
56. Franceschi S, Preston-Martin S, Dal Maso L, et al. A pooled analysis of case-control studies of thyroid cancer. IV. Benign thyroid diseases. Cancer Causes Control 1999;10:583-595.